Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (441-450 of 477) with videos related to

Pageof 48
Sort By:
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
Annals of Internal Medicine|November 6, 2002
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialJoel M Kremer, Mark C Genovese, Grant W Cannon, et al.
Arthritis Care & Research|November 8, 2015
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisJasvinder A Singh, Kenneth G Saag, S Louis Bridges, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 8, 2015
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisJasvinder A Singh, Kenneth G Saag, S Louis Bridges, et al.
Arthritis Care & Research|April 17, 2012
Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baselineLoreto Massardo, Bernardo A Pons-Estel, Daniel Wojdyla, et al.
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
Pageof 48

Showing results (441-450 of 477) with videos related to

Sort By:
Pageof 48
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
Annals of Internal Medicine|November 6, 2002
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trialJoel M Kremer, Mark C Genovese, Grant W Cannon, et al.
Arthritis Care & Research|November 8, 2015
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisJasvinder A Singh, Kenneth G Saag, S Louis Bridges, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 8, 2015
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisJasvinder A Singh, Kenneth G Saag, S Louis Bridges, et al.
Arthritis Care & Research|April 17, 2012
Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baselineLoreto Massardo, Bernardo A Pons-Estel, Daniel Wojdyla, et al.
Seminars in Arthritis and Rheumatism|April 20, 2021
OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods studySabrina Mai Nielsen, Maarten Boers, Maarten de Wit, et al.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Rheumatology|March 18, 2014
Updating the OMERACT filter: core areas as a basis for defining core outcome setsJohn R Kirwan, Maarten Boers, Sarah Hewlett, et al.
Pageof 48